Kinase inhibition in autoimmunity and inflammation (Q100737257)

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Acute respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Human autoimmune diseases: a comprehensive update

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Systemic autoinflammatory diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Immune Checkpoints as Therapeutic Targets in Autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Kinase inhibitors: the road ahead.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Targeting protein kinases for the development of anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Safety of combination therapy with two bDMARDs in patients with rheumatoid arthritis: A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Transcriptional control of the inflammatory response

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

The non-canonical NF-κB pathway in immunity and inflammation

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Mitogen-activated protein kinases in innate immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Immunological memory: lessons from the past and a look to the future

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

The functional plasticity of T cell subsets

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Regulatory T cells in skin injury: At the crossroads of tolerance and tissue repair

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

The Other Function: Class II-Restricted Antigen Presentation by B Cells

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Innate and Adaptive Immune Memory: an Evolutionary Continuum in the Host's Response to Pathogens

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Structural principles of tumor necrosis factor superfamily signaling

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

The family of the interleukin-1 receptors

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

The pro- and anti-inflammatory properties of the cytokine interleukin-6.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

New directions in the basic and translational biology of interleukin-27.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Pattern recognition receptors and inflammation

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Structural Basis for the Non-catalytic Functions of Protein Kinases.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

The secret life of kinases: functions beyond catalysis

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Tezepelumab in Adults with Uncontrolled Asthma

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Development of gut-selective pan-Janus kinase inhibitor TD-1473 for ulcerative colitis: A translational medicine program

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Helical assembly in the MyD88–IRAK4–IRAK2 complex in TLR/IL-1R signalling

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

IRAK4 dimerization and trans-autophosphorylation are induced by Myddosome assembly

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

TRAF6 is a signal transducer for interleukin-1

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Interleukin-1 (IL-1) receptor-associated kinase-dependent IL-1-induced signaling complexes phosphorylate TAK1 and TAB2 at the plasma membrane and activate TAK1 in the cytosol

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Interleukin-1 receptor-associated kinase 2 is critical for lipopolysaccharide-mediated post-transcriptional control.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Distinct molecular mechanism for initiating TRAF6 signalling

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

IRAK2 directs stimulus-dependent nuclear export of inflammatory mRNAs.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

IRAK-M is a negative regulator of Toll-like receptor signaling

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

IRAK-M mediates Toll-like receptor/IL-1R-induced NFκB activation and cytokine production

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

The interleukin-1 receptor-associated kinase M selectively inhibits the alternative, instead of the classical NFkappaB pathway

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Cofactors required for TLR7- and TLR9-dependent innate immune responses

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Evidence for licensing of IFN-gamma-induced IFN regulatory factor 1 transcription factor by MyD88 in Toll-like receptor-dependent gene induction program

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Interferon-regulatory-factor 1 controls Toll-like receptor 9-mediated IFN-β production in myeloid dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor-mediated immune responses but not in TCR signaling

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

IL-1 receptor-associated kinase modulates host responsiveness to endotoxin.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

IRAK-4 kinase activity is required for interleukin-1 (IL-1) receptor- and toll-like receptor 7-mediated signaling and gene expression

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Deficiency in IRAK4 activity attenuates manifestations of murine Lupus

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Suppression of IRAK1 or IRAK4 Catalytic Activity, but Not Type 1 IFN Signaling, Prevents Lupus Nephritis in Mice Expressing a Ubiquitin Binding-Defective Mutant of ABIN1

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Genetic ablation of IRAK4 kinase activity inhibits vascular lesion formation

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Loss of interleukin receptor-associated kinase 4 signaling suppresses amyloid pathology and alters microglial phenotype in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Inherited human IRAK-1 deficiency selectively impairs TLR signaling in fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Inflammation: Species-specific TLR signalling -- insight into human disease

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Experimental and natural infections in MyD88- and IRAK-4-deficient mice and humans

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Two phases of inflammatory mediator production defined by the study of IRAK2 and IRAK1 knock-in mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Human Interleukin-1 Receptor-associated Kinase-2 Is Essential for Toll-like Receptor-mediated Transcriptional and Post-transcriptional Regulation of Tumor Necrosis Factor α

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

A narrow repertoire of transcriptional modules responsive to pyogenic bacteria is impaired in patients carrying loss-of-function mutations in MYD88 or IRAK4

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Mechanism of dysfunction of human variants of the IRAK4 kinase and a role for its kinase activity in interleukin-1 receptor signaling

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a dual role in myddosome formation and Toll-like receptor signaling

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

The diverse role of RIP kinases in necroptosis and inflammation

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Diverse ubiquitin linkages regulate RIP kinases-mediated inflammatory and cell death signaling

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

RIPK1 and RIPK3: critical regulators of inflammation and cell death

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Intracellular regulation of TNF activity in health and disease

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Multitasking Kinase RIPK1 Regulates Cell Death and Inflammation

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Coordinated ubiquitination and phosphorylation of RIP1 regulates necroptotic cell death.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

RIP3 induces apoptosis independent of pronecrotic kinase activity

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Cytotoxicity of crystals involves RIPK3-MLKL-mediated necroptosis

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

RIP1 kinase activity is critical for skin inflammation but not for viral propagation

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

IL-13-induced airway mucus production is attenuated by MAPK13 inhibition

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

NF-κB-Independent Role of IKKα/IKKβ in Preventing RIPK1 Kinase-Dependent Apoptotic and Necroptotic Cell Death during TNF Signaling.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Regulation of RIPK1 activation by TAK1-mediated phosphorylation dictates apoptosis and necroptosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Cleavage of RIPK1 by caspase-8 is crucial for limiting apoptosis and necroptosis

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Autophagy protein ATG16L1 prevents necroptosis in the intestinal epithelium.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Targeting RIPK1 for the treatment of human diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

NOD1 and NOD2: signaling, host defense, and inflammatory disease

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

The Ubiquitin Ligase XIAP Recruits LUBAC for NOD2 Signaling in Inflammation and Innate Immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Disruption of XIAP-RIP2 Association Blocks NOD2-Mediated Inflammatory Signaling

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

TEC-family kinases: regulators of T-helper-cell differentiation

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Tec family kinases modulate thresholds for thymocyte development and selection

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Apoptosis by death factor

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Ibrutinib treatment improves T cell number and function in CLL patients

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Defective B cell development and function in Btk-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Type I and III Interferon Productions Are Impaired in X-Linked Agammaglobulinemia Patients Toward Poliovirus but Not Influenza Virus

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Fcgamma receptors as regulators of immune responses

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Tyrosine phosphorylation and activation of Bruton tyrosine kinase upon Fc epsilon RI cross-linking

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Involvement of Bruton's tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Requirement of phospholipase C-gamma 2 activation in surface immunoglobulin M-induced B cell apoptosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Phospholipase Cgamma2 is essential in the functions of B cell and several Fc receptors

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Bruton's tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton's Tyrosine Kinase.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Btk inhibition treats TLR7/IFN driven murine lupus

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

The BTK-inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

The SYK tyrosine kinase: a crucial player in diverse biological functions

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Structural and biophysical characterization of the Syk activation switch

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Structural basis for the inhibition of tyrosine kinase activity of ZAP-70

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Syk activation and dissociation from the B-cell antigen receptor is mediated by phosphorylation of tyrosine 130

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Cbl-mediated negative regulation of the Syk tyrosine kinase. A critical role for Cbl phosphotyrosine-binding domain binding to Syk phosphotyrosine 323

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Getting Syk: spleen tyrosine kinase as a therapeutic target.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Syk-dependent signaling pathways in neutrophils and macrophages are indispensable in the pathogenesis of anti-collagen antibody-induced arthritis.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Syk tyrosine kinase required for mouse viability and B-cell development

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Fostamatinib: First Global Approval.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Fostamatinib for persistent/chronic adult immune thrombocytopenia.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Distinct roles for the linker region tyrosines of Syk in FcepsilonRI signaling in primary mast cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

TPL2 kinase action and control of inflammation.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Lipopolysaccharide activation of the TPL-2/MEK/extracellular signal-regulated kinase mitogen-activated protein kinase cascade is regulated by IkappaB kinase-induced proteolysis of NF-kappaB1 p105.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

ABIN-2 forms a ternary complex with TPL-2 and NF-kappa B1 p105 and is essential for TPL-2 protein stability

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

NF-kappaB1 p105 negatively regulates TPL-2 MEK kinase activity

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Tpl2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specific manner.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

TPL2-mediated activation of ERK1 and ERK2 regulates the processing of pre-TNF in LPS-stimulated macrophages

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

NF-kappaB1/p105 regulates lipopolysaccharide-stimulated MAP kinase signaling by governing the stability and function of the Tpl2 kinase

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Regulation of experimental autoimmune encephalomyelitis by TPL-2 kinase

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

ABIN2 Function Is Required To Suppress DSS-Induced Colitis by a Tpl2-Independent Mechanism

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Intestinal myofibroblast-specific Tpl2-Cox-2-PGE2 pathway links innate sensing to epithelial homeostasis.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

p38 MAP-kinases pathway regulation, function and role in human diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Differential activation of p38MAPK isoforms by MKK6 and MKK3.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Characterization of the Structure and Function of the Fourth Member of p38 Group Mitogen-activated Protein Kinases, p38δ

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

p38γ and p38δ kinases regulate the Toll-like receptor 4 (TLR4)-induced cytokine production by controlling ERK1/2 protein kinase pathway activation

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Eukaryotic elongation factor 2 controls TNF-α translation in LPS-induced hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

TPL2 meets p38MAPK: emergence of a novel positive feedback loop in inflammation

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Alternative p38 MAPKs are essential for collagen-induced arthritis.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Regulation of PTEN activity by p38δ-PKD1 signaling in neutrophils confers inflammatory responses in the lung

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Regulation of PKD by the MAPK p38delta in insulin secretion and glucose homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Essential role of p38gamma in K-Ras transformation independent of phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

p38 Mitogen-activated protein kinase inhibitors: a review on pharmacophore mapping and QSAR studies

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

p38(MAPK): stress responses from molecular mechanisms to therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Selective inhibition of the p38α MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and -γ selectivity, suppresses COPD inflammation.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Pirfenidone gel in patients with localized scleroderma: a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Pirfenidone for diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Comparative chemical array screening for p38γ/δ MAPK inhibitors using a single gatekeeper residue difference between p38α/β and p38γ/δ

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

ERK5: structure, regulation and function.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Function of CSF1 and IL34 in Macrophage Homeostasis, Inflammation, and Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Recent advances in colony stimulating factor-1 receptor/c-FMS as an emerging target for various therapeutic implications.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Molecular cloning of mouse ERK5/BMK1 splice variants and characterization of ERK5 functional domains

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

The unique C-terminal tail of the mitogen-activated protein kinase ERK5 regulates its activation and nuclear shuttling.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Extracellular signal-regulated kinase 5 promotes acute cellular and systemic inflammation

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

ERK5 kinase activity is dispensable for cellular immune response and proliferation

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

ERK5 is a critical mediator of inflammation-driven cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Mechanisms of type-I- and type-II-interferon-mediated signalling

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Genetic interferonopathies: An overview

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Type I interferonopathies in pediatric rheumatology

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Human TBK1: A Gatekeeper of Neuroinflammation

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Ubiquitin-specific protease 2b negatively regulates IFN-β production and antiviral activity by targeting TANK-binding kinase 1.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Cutting Edge: Inhibiting TBK1 by Compound II Ameliorates Autoimmune Disease in Mice

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Dendritic cells require NIK for CD40-dependent cross-priming of CD8+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Conditional Deletion of NF-κB-Inducing Kinase (NIK) in Adult Mice Disrupts Mature B Cell Survival and Activation.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

A conserved Mediator-CDK8 kinase module association regulates Mediator-RNA polymerase II interaction

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Cell cycle, CDKs and cancer: a changing paradigm

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Inhibition of Cdk8/Cdk19 Activity Promotes Treg Cell Differentiation and Suppresses Autoimmune Diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Conversion of antigen-specific effector/memory T cells into Foxp3-expressing Treg cells by inhibition of CDK8/19

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Turning the Tide Against Regulatory T Cells

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Artificial intelligence in drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Specific delivery of kinase inhibitors in nonmalignant and malignant diseases.

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Regulation and function of NF-kappaB transcription factors in the immune system

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021

Innate immune recognition of DNA: A recent history

1 reference

https://api.crossref.org/works/10.1038%2FS41573-020-0082-8

7 January 2021